Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2023 | Promising novel agents for hemophilia A/B: gene therapies and extended half-life products

Azusa Nagao • 27 Jun 2023
ISTH 2023
Hemophilia Non-Malignant

Azusa Nagao, MD, Ogikubo Hospital, Tokyo, Japan, briefly discusses promising novel agents being investigated for hemophilia A and B. Dr Nagao comments on the current state of research, particularly regarding gene therapies and extended half-life products, in Japan and the USA. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Azusa Nagao

2:58
Long-term joint outcomes in patients with hemophilia: three-year results from the J-DaUPHIN study
Azusa Nagao • 27 Jun 2023
1:17
Albutrepenonacog alfa in Japanese patients with hemophilia B
Azusa Nagao • 27 Jun 2023

Related Videos

1:09
Improving the mental health and psychological resilience of patients with SCD
Marsha Treadwell • 29 Apr 2024
4:38
Patient selection for investigating the use of heparin as thromboprophylaxis in pregnancy
Beverley Hunt • 29 Apr 2024
2:34
A national physician survey investigating the management of pulmonary thromboembolism in pregnancy
Giulia Simini • 29 Apr 2024
1:39
Considering the use of gene therapy in severe inherited thrombophilia
Beverley Hunt • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals